Current Rating and Its Significance
MarketsMOJO’s 'Sell' rating for Concord Drugs Ltd indicates a cautious stance towards the stock, suggesting that investors may want to consider reducing exposure or avoiding new purchases at this time. This rating is derived from a comprehensive evaluation of four key parameters: Quality, Valuation, Financial Trend, and Technicals. The rating was revised on 23 February 2026, when the Mojo Score declined by 10 points from 51 to 41, reflecting a shift in the company’s outlook. Despite the rating change date, it is essential to understand the stock’s present-day fundamentals and market behaviour as of 21 April 2026 to make informed investment decisions.
Quality Assessment: Below Average Fundamentals
As of 21 April 2026, Concord Drugs Ltd exhibits below average quality metrics. The company’s long-term fundamental strength remains weak, with a compound annual growth rate (CAGR) in net sales of -2.47% over the past five years. This negative growth trend signals challenges in expanding revenue streams, which is a critical concern for investors seeking sustainable growth.
Profitability metrics further underline the quality concerns. The average Return on Equity (ROE) stands at a modest 2.23%, indicating limited efficiency in generating profits from shareholders’ funds. Additionally, the company’s ability to service debt is constrained, with a high Debt to EBITDA ratio of 3.76 times, suggesting elevated financial risk and potential liquidity pressures.
Valuation: Fair but Not Compelling
Currently, Concord Drugs Ltd’s valuation is graded as fair. While the stock does not appear excessively overvalued, it also lacks the attractive pricing that might entice value investors. The fair valuation grade implies that the market price reasonably reflects the company’s earnings and growth prospects, but does not offer a significant margin of safety or upside potential relative to peers or historical averages.
Financial Trend: Flat Performance and Profitability Challenges
The financial trend for Concord Drugs Ltd is largely flat, with recent quarterly results underscoring operational difficulties. The December 2025 quarter reported the lowest PBDIT (Profit Before Depreciation, Interest and Taxes) at ₹0.95 crore, alongside an operating profit to net sales ratio of just 5.59%, the lowest recorded in recent periods. These figures highlight subdued operational efficiency and margin pressures, which weigh on the company’s overall financial health.
Despite these challenges, the stock has delivered strong returns over the past year, with a 1-year return of +172.29% as of 21 April 2026. This performance, however, may be influenced by market speculation or sector-specific factors rather than underlying fundamental improvements.
Technical Outlook: Mildly Bullish Momentum
From a technical perspective, Concord Drugs Ltd shows mildly bullish signals. The stock has gained 2.07% on the day and recorded positive returns over multiple time frames: +10.14% over one week, +11.37% over one month, and +37.95% over six months. This upward momentum suggests some investor confidence and buying interest in the near term, although it is tempered by the company’s fundamental weaknesses.
Implications for Investors
The 'Sell' rating reflects a cautious approach given the company’s below average quality, flat financial trend, and fair valuation. While technical indicators show some positive momentum, the underlying fundamentals do not support a more optimistic outlook. Investors should carefully weigh the risks associated with Concord Drugs Ltd, particularly its weak revenue growth, low profitability, and high leverage.
For those holding the stock, this rating suggests monitoring developments closely and considering portfolio adjustments if the company’s fundamentals do not improve. Prospective investors might prefer to explore alternatives with stronger growth prospects and healthier financial profiles within the Pharmaceuticals & Biotechnology sector.
Our latest monthly pick, this Large Cap from Aluminium & Aluminium Products, is outperforming the market! See the analysis that helped our Investment Committee select this winner.
- - Market-beating performance
- - Committee-backed winner
- - Aluminium & Aluminium Products standout
Sector Context and Market Capitalisation
Concord Drugs Ltd operates within the Pharmaceuticals & Biotechnology sector, a space characterised by innovation, regulatory challenges, and competitive pressures. The company is classified as a microcap, which often entails higher volatility and risk compared to larger, more established peers. Investors should consider these sector dynamics alongside the company’s specific financial and operational metrics when evaluating the stock.
Summary of Key Metrics as of 21 April 2026
To summarise, the stock’s Mojo Score stands at 41.0, corresponding to a 'Sell' grade. The quality grade is below average, valuation is fair, financial trend is flat, and technical grade is mildly bullish. Stock returns have been strong over the past year, but this performance contrasts with the company’s weak fundamentals and operational challenges.
In conclusion, the current 'Sell' rating by MarketsMOJO for Concord Drugs Ltd reflects a comprehensive assessment of the company’s present-day financial health and market position. Investors should approach the stock with caution, recognising the risks posed by its weak growth, profitability constraints, and leverage, despite some positive technical signals and recent price appreciation.
Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →
